Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

NCT06644313 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT06644313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06644313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
November 1, 2029
Enrollment
31 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

potentially resectable met-altered non-small cell lung cancer